Analyst firms · Raymond James · NTRA
Raymond James NTRA price target and rating history
Natera Inc. (NTRA) · Health Care
Raymond James rates Natera Inc. (NTRA) Outperform with a $85 price target, as of its latest action on Feb 20, 2024. It has published 3 rating actions on NTRA since January 2023, including 2 upgrades and 1 downgrade. Across 8 firms with a NTRA price target in the last 12 months, the median target is $305.
- Current rating
- Outperform
- Price target
- $85
- Median target, all firms
- $305
- Actions on NTRA
- 3
Raymond James price target on NTRA
Every Raymond James rating on NTRA
- Feb 20, 2024
- Nov 13, 2023
- Jan 18, 2023
How other firms rate NTRA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $475 | Oct 23, 2026 |
| UBS | Buy | $435 | Sep 9, 2026 |
| Rothschild & Co Redburn | Buy | $385 | Sep 8, 2026 |
| Bernstein | Outperform | $310 | Jun 26, 2026 |
| RBC Capital Markets | Outperform | $275 | Jun 12, 2026 |
| Wolfe Research | Outperform | $260 | Jun 2, 2026 |
| William Blair | Outperform | Apr 14, 2026 | |
| Citigroup | Buy | $300 | Jan 7, 2026 |
| Morgan Stanley | Overweight | $265 | Dec 2, 2025 |
Questions about Raymond James and NTRA
- What is Raymond James's price target for NTRA?
- Raymond James's latest stated price target for Natera Inc. (NTRA) is $85, from its action on Feb 20, 2024.
- What is Raymond James's rating on NTRA?
- Raymond James rates NTRA Outperform, a bullish rating, as of Feb 20, 2024.
- When did Raymond James last change its view on NTRA?
- On Feb 20, 2024, Raymond James downgrades to Outperform from Strong Buy, price target $68 to $85.
- How does Raymond James's NTRA target compare with other analysts?
- Across 8 firms with a NTRA price target in the last 12 months, the median target is $305.
More NTRA rating histories
All Raymond James ratingsNTRA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.